Evidence map›Paper›PMID 41580787›Full record

ArticleBMC medical genomics2026

Discovery of new MicroRNAs and their mRNA targets in patients with acute ischemic stroke.

Ceren Eyileten, Zofia Wicik, Aleksandra Gasecka, Sara Ahmadova, Maria Teresa Di Martino, Joanna Mucha, Dagmara Mirowska-Guzel, Salvatore De Rosa, Iwona Kurkowska-Jastrzebska, Anna Czlonkowska and 1 more

Abstract read
In one paragraph

Article in BMC medical genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ceren EyiletenDepartment of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology (CePT), Medical University of Warsaw, Warsaw, 02-091, Poland.ORCID http://orcid.org/0000-0002-3324-9625
Zofia WicikDepartment of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology (CePT), Medical University of Warsaw, Warsaw, 02-091, Poland.ORCID http://orcid.org/0000-0002-2857-1986
Aleksandra Gasecka1st Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, 02-091, Poland.ORCID http://orcid.org/0000-0001-5083-7587
Sara AhmadovaDepartment of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology (CePT), Medical University of Warsaw, Warsaw, 02-091, Poland.ORCID http://orcid.org/0009-0001-0499-2735
Maria Teresa Di MartinoDepartment of Experimental and Clinical Medicine (DMSC), Magna Graecia University, Catanzaro, 88100, Italy.ORCID http://orcid.org/0000-0002-8205-2706
Joanna MuchaDepartment of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology (CePT), Medical University of Warsaw, Warsaw, 02-091, Poland.ORCID http://orcid.org/0000-0001-8322-8155
Dagmara Mirowska-GuzelDepartment of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology (CePT), Medical University of Warsaw, Warsaw, 02-091, Poland.ORCID http://orcid.org/0000-0001-6294-3256
Salvatore De RosaDivision of Cardiology, Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, 88100, Italy.ORCID http://orcid.org/0000-0001-5388-942X
Iwona Kurkowska-Jastrzebska2nd Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, 02-957, Poland.ORCID http://orcid.org/0000-0001-6553-9080
Anna Czlonkowska2nd Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, 02-957, Poland.ORCID http://orcid.org/0000-0002-1956-1866
Marek PostulaDepartment of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology (CePT), Medical University of Warsaw, Warsaw, 02-091, Poland. marek.postula@wum.edu.pl.ORCID http://orcid.org/0000-0002-7826-4458

Funding

Narodowe Centrum Nauki 2018/31/B/NZ7/01137
6 · The paper itself

Abstract

backgroundIn this study, we applied microarray, bioinformatics, and qRT-PCR techniques to identify miRNAs and their target genes in plasma obtained from acute ischemic stroke patients and matching controls.

methodsMicroarray analyses were performed with 24-h acute ischemic stroke vs. healthy individuals and CV-risk factors matched control group plasma samples. Statistical analysis of gene expression was performed using TAC and R, with a focus on robust methods suitable for the small sample size, and miRNA target prediction was conducted using a previously established in-house wizbionet R package. Top non-coding regulators of ischemia (miR-18a-5p, miR-4467, miR-199a-5p and miR-3135b) and their predicted target genes (ANKRD12, HIF1A, GNAI2, GRIN1) were detected via qRT-PCR.

results146 upregulated and 258 downregulated differentially expressed RNAs were detected by microarray analysis. Using the multiMiR R package for target prediction, 67 upregulated and 125 downregulated mRNAs were mapped. Functional enrichment analysis revealed that upregulated miRNAs were associated with pathways like BDNF and IL-2 signaling, while downregulated miRNAs were linked to neurodevelopmental and NGF pathways. MiR-18a-5p and miR-199a-5p were significantly elevated in stroke patients at both day 1 and day 7 compared to healthy individuals and CV-matched controls (p < 0.05 for all). miR-4467 was lower at day 1 versus both controls (p < 0.05) but markedly increased by day 7 (p < 0.001), remaining higher than in controls (p < 0.05). miR-3135b showed persistent downregulation at both time points (p < 0.05). ROC analysis confirmed diagnostic value for all miRNAs, with the highest AUC for miR-199a-5p (0.89, 95% CI: 0.81–0.97, p < 0.001), followed by miR-3135b (0.88), miR-4467 (0.80), and miR-18a-5p (0.73; p = 0.002). For potential role in dynamic post-stroke molecular responses perspective, utility, miR-4467 increased significantly during hospitalization (p < 0.001). GNAI2 mRNA was significantly elevated at day 1 versus controls (p < 0.05). ANKRD12 was consistently lower at both day 1 and day 7 compared to controls (p < 0.05). GRIN1 was reduced at admission (p = 0.006) but normalized by day 7 (p > 0.05). ROC analysis showed diagnostic significance for ANKRD12, GNAI2, and GRIN1 (AUC = 0.683, 0.698, 0.693).

conclusionOur integrated miRNA/mRNA analysis identified distinct molecular signatures in acute ischemic stroke, with 146 upregulated and 258 downregulated RNAs, implicating key neuroinflammatory and neuroprotective pathways, including BDNF, IL-2, and NGF signaling. Among the validated candidates, miR-199a-5p, miR-3135b, miR-4467, and miR-18a-5p demonstrated diagnostic potential, while miR-4467, together with GNAI2 and HIF1A, showed post-stroke dynamic relevance, reflecting early transcriptomic adaptations following ischemic injury.

Indexed as

Brain IschemiaIschemic StrokeMicroRNAsRNA, MessengerStrokeAgedCase-Control StudiesFemaleGene Expression ProfilingGene Expression RegulationHumansMaleMiddle AgedOligonucleotide Array Sequence AnalysisMicroRNAsRNA, MessengerANKRD12BioinformaticDiagnosisGNAI2GRIN1IschemiamiR-18a-5pmiR-199a-5pmiR-3135bmiR-4467Prognosis

Identifiers

PMID41580787
PMCPMC12911278

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.